Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Anne Fuhlbrigge

Concepts (426)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Asthma
94
2023
2051
9.470
 Why?
Adrenal Cortex Hormones
26
2023
499
3.230
 Why?
Anti-Asthmatic Agents
26
2022
350
3.060
 Why?
Forced Expiratory Volume
19
2019
476
1.690
 Why?
Pulmonary Disease, Chronic Obstructive
11
2022
928
1.520
 Why?
Severity of Illness Index
20
2020
2551
1.100
 Why?
Anti-Inflammatory Agents
10
2016
451
0.960
 Why?
Lung Transplantation
10
2017
246
0.960
 Why?
Administration, Inhalation
23
2022
641
0.920
 Why?
Albuterol
5
2015
103
0.900
 Why?
Bronchodilator Agents
12
2016
243
0.870
 Why?
Budesonide
14
2016
87
0.850
 Why?
Self Report
3
2023
698
0.780
 Why?
Humans
123
2023
115044
0.780
 Why?
Nedocromil
11
2016
32
0.780
 Why?
Nasal Polyps
1
2021
49
0.760
 Why?
Pharmacogenetics
2
2015
149
0.740
 Why?
Endpoint Determination
2
2020
69
0.740
 Why?
Sinusitis
1
2021
175
0.670
 Why?
Lung
7
2019
3595
0.660
 Why?
Hospitalization
13
2020
1754
0.660
 Why?
Physicians
2
2021
772
0.650
 Why?
Virus Diseases
1
2021
196
0.640
 Why?
Sleep Apnea, Obstructive
1
2021
194
0.620
 Why?
Glucocorticoids
4
2022
535
0.620
 Why?
Food Hypersensitivity
1
2022
254
0.610
 Why?
Symptom Assessment
1
2019
118
0.600
 Why?
Child
53
2022
18407
0.590
 Why?
Disease Progression
14
2020
2389
0.580
 Why?
Oxygen Inhalation Therapy
4
2020
129
0.570
 Why?
Emergency Service, Hospital
9
2013
1811
0.560
 Why?
Male
79
2020
55731
0.560
 Why?
Bone Density
2
2014
432
0.560
 Why?
Androstadienes
3
2012
97
0.550
 Why?
Patient Reported Outcome Measures
1
2018
250
0.540
 Why?
Adult
44
2023
30656
0.540
 Why?
Precision Medicine
1
2020
340
0.540
 Why?
Managed Care Programs
8
2008
134
0.530
 Why?
Female
78
2020
59614
0.530
 Why?
Practice Patterns, Physicians'
7
2020
1177
0.500
 Why?
Cost Savings
1
2015
74
0.480
 Why?
Adrenergic beta-2 Receptor Agonists
4
2020
32
0.480
 Why?
Middle Aged
37
2020
26827
0.460
 Why?
Cost-Benefit Analysis
7
2022
544
0.440
 Why?
Peak Expiratory Flow Rate
2
2011
33
0.440
 Why?
Comorbidity
4
2021
1457
0.410
 Why?
Adolescent
36
2019
17864
0.390
 Why?
Surveys and Questionnaires
13
2022
4631
0.380
 Why?
Remote Consultation
2
2022
42
0.370
 Why?
Mentors
1
2012
158
0.370
 Why?
Child, Preschool
31
2016
9093
0.370
 Why?
Administration, Oral
6
2021
730
0.370
 Why?
United States
22
2022
12226
0.370
 Why?
Medical Records Systems, Computerized
3
2008
90
0.360
 Why?
Respiratory Function Tests
10
2015
523
0.360
 Why?
Faculty, Medical
1
2012
232
0.350
 Why?
Medication Adherence
3
2023
537
0.350
 Why?
Child Development
1
2014
389
0.340
 Why?
Aged
22
2022
19119
0.340
 Why?
Interprofessional Relations
3
2021
251
0.340
 Why?
Spirometry
8
2020
225
0.340
 Why?
Treatment Outcome
15
2017
9122
0.340
 Why?
Oxygen
3
2018
855
0.320
 Why?
Group Practice
1
2008
7
0.310
 Why?
Computer Simulation
1
2012
880
0.310
 Why?
Anti-Allergic Agents
2
2008
41
0.310
 Why?
Phenotype
5
2021
2815
0.300
 Why?
Quality of Life
11
2023
2359
0.300
 Why?
Dyspnea
3
2022
218
0.290
 Why?
Follow-Up Studies
17
2017
4420
0.280
 Why?
Drug Utilization
4
2005
167
0.270
 Why?
Primary Graft Dysfunction
2
2017
32
0.260
 Why?
Randomized Controlled Trials as Topic
7
2020
1214
0.260
 Why?
Quality Assurance, Health Care
1
2008
314
0.260
 Why?
Genetic Testing
1
2008
380
0.260
 Why?
Bronchiolitis Obliterans
3
2017
66
0.250
 Why?
Gift Giving
1
2005
9
0.250
 Why?
Respiratory Sounds
1
2006
111
0.250
 Why?
Diagnostic Techniques, Respiratory System
1
2005
5
0.250
 Why?
Allergists
2
2022
19
0.250
 Why?
Delivery of Health Care
2
2021
835
0.250
 Why?
Leadership
2
2022
295
0.240
 Why?
Cohort Studies
14
2013
4904
0.240
 Why?
Retrospective Studies
17
2022
12547
0.240
 Why?
Antibodies, Monoclonal
2
2008
1268
0.240
 Why?
Time Factors
10
2020
6141
0.240
 Why?
Massachusetts
5
2016
136
0.230
 Why?
Young Adult
11
2019
10498
0.230
 Why?
Recurrence
5
2013
941
0.220
 Why?
Genetic Variation
1
2008
876
0.220
 Why?
Health Status
1
2008
722
0.210
 Why?
Predictive Value of Tests
9
2012
1812
0.210
 Why?
Steroids
8
2011
147
0.210
 Why?
Rhinitis, Allergic, Perennial
1
2003
23
0.210
 Why?
Prevalence
4
2022
2255
0.210
 Why?
Multicenter Studies as Topic
4
2018
250
0.210
 Why?
Biomarkers
3
2021
3419
0.210
 Why?
Beclomethasone
1
2022
25
0.200
 Why?
Models, Theoretical
4
2007
517
0.190
 Why?
Academic Medical Centers
2
2022
412
0.190
 Why?
Social Class
2
2022
205
0.190
 Why?
Patient Preference
1
2023
169
0.190
 Why?
Tiotropium Bromide
2
2018
18
0.190
 Why?
Nebulizers and Vaporizers
2
2020
78
0.190
 Why?
Desensitization, Immunologic
1
2022
117
0.180
 Why?
Risk Factors
12
2018
8643
0.180
 Why?
Churg-Strauss Syndrome
1
2020
17
0.180
 Why?
Bronchoconstriction
3
2011
27
0.180
 Why?
Capacity Building
1
2021
51
0.180
 Why?
Physician-Patient Relations
2
2021
463
0.180
 Why?
Pulmonologists
1
2020
16
0.180
 Why?
Granulomatosis with Polyangiitis
1
2020
41
0.180
 Why?
Air Pollution, Indoor
2
2002
108
0.180
 Why?
Muscarinic Antagonists
1
2020
26
0.180
 Why?
Agammaglobulinemia
1
2020
29
0.170
 Why?
Practice Guidelines as Topic
5
2020
1398
0.170
 Why?
Specialization
1
2021
115
0.170
 Why?
Exercise Test
1
2022
545
0.160
 Why?
Prognosis
8
2017
3334
0.160
 Why?
Treatment Adherence and Compliance
1
2019
18
0.160
 Why?
Primary Health Care
4
2021
1512
0.160
 Why?
Receptors, IgE
2
2009
40
0.160
 Why?
Vitamin D
2
2012
340
0.150
 Why?
Biological Products
1
2020
171
0.150
 Why?
Fossil Fuels
1
1997
8
0.150
 Why?
Allergens
1
2021
417
0.150
 Why?
Aged, 80 and over
6
2019
6357
0.140
 Why?
Drug Prescriptions
2
2011
239
0.140
 Why?
Alemtuzumab
1
2017
12
0.140
 Why?
Photopheresis
1
2017
9
0.140
 Why?
Hypersensitivity
1
2020
256
0.140
 Why?
Respiration
1
2017
182
0.140
 Why?
Emergency Medical Services
2
2007
587
0.140
 Why?
Respiration Disorders
1
1997
68
0.140
 Why?
Drug Combinations
3
2012
287
0.140
 Why?
Physicians, Primary Care
3
2021
222
0.140
 Why?
Immunomodulation
1
2017
84
0.130
 Why?
Drug Therapy, Combination
5
2020
955
0.130
 Why?
Statistics, Nonparametric
1
2017
387
0.130
 Why?
Patient Admission
1
2018
175
0.130
 Why?
Referral and Consultation
1
2021
633
0.130
 Why?
Immunoglobulin G
1
2020
776
0.130
 Why?
Postoperative Complications
2
2017
2150
0.130
 Why?
Breath Tests
2
2008
83
0.130
 Why?
Scopolamine Derivatives
1
2015
6
0.130
 Why?
Embolism, Fat
1
2015
10
0.130
 Why?
Longitudinal Studies
6
2017
2389
0.130
 Why?
Genomics
2
2018
641
0.130
 Why?
Tobacco Smoke Pollution
2
2010
217
0.130
 Why?
Cholinergic Antagonists
1
2015
27
0.130
 Why?
Transplants
1
2015
36
0.130
 Why?
National Heart, Lung, and Blood Institute (U.S.)
1
2015
94
0.130
 Why?
Fluticasone-Salmeterol Drug Combination
2
2012
12
0.130
 Why?
Overweight
2
2011
474
0.130
 Why?
Carcinoma, Bronchogenic
1
2015
17
0.120
 Why?
Telemedicine
1
2023
665
0.120
 Why?
Respiratory Tract Infections
2
2012
321
0.120
 Why?
Graft Rejection
2
2013
522
0.120
 Why?
Environmental Exposure
3
2006
377
0.120
 Why?
Quality Improvement
1
2022
953
0.120
 Why?
Ambulatory Care Information Systems
2
2005
5
0.120
 Why?
Guideline Adherence
3
2020
492
0.120
 Why?
Prednisolone
1
2014
76
0.110
 Why?
Risk
4
2015
815
0.110
 Why?
Education, Medical, Continuing
2
2005
119
0.110
 Why?
Antibodies, Monoclonal, Humanized
2
2008
665
0.110
 Why?
Forecasting
1
2015
332
0.110
 Why?
Peer Group
2
2012
203
0.110
 Why?
Bronchial Hyperreactivity
3
2010
95
0.110
 Why?
Medicare
2
2022
666
0.110
 Why?
Transplantation
1
2013
23
0.110
 Why?
Double-Blind Method
5
2010
1664
0.110
 Why?
Airway Obstruction
1
2015
168
0.110
 Why?
Office Visits
4
2011
79
0.110
 Why?
Insurance Claim Review
1
2013
67
0.110
 Why?
Research
1
2015
395
0.100
 Why?
Costs and Cost Analysis
1
2013
196
0.100
 Why?
Growth
1
2012
56
0.100
 Why?
Methacholine Chloride
3
2008
47
0.100
 Why?
Feedback
1
2012
146
0.100
 Why?
Metered Dose Inhalers
1
2012
14
0.100
 Why?
Logistic Models
5
2017
1839
0.100
 Why?
Mycoses
1
2012
66
0.100
 Why?
Cytomegalovirus Infections
2
2012
182
0.100
 Why?
Drug Dosage Calculations
1
2011
21
0.100
 Why?
Socioeconomic Factors
3
2022
1081
0.100
 Why?
Obesity
3
2015
2524
0.100
 Why?
Antifungal Agents
1
2012
129
0.100
 Why?
Body Height
1
2012
180
0.100
 Why?
Effect Modifier, Epidemiologic
1
2011
12
0.100
 Why?
Multivariate Analysis
7
2017
1435
0.100
 Why?
Morbidity
2
2022
279
0.090
 Why?
Professional Role
1
2012
152
0.090
 Why?
Medication Errors
1
2012
89
0.090
 Why?
Patient Readmission
1
2016
606
0.090
 Why?
Epidemiologic Studies
1
2011
57
0.090
 Why?
Diagnostic Errors
1
2012
151
0.090
 Why?
Mycobacterium
1
2012
103
0.090
 Why?
Pneumococcal Vaccines
1
2012
132
0.090
 Why?
Secondary Prevention
1
2012
222
0.090
 Why?
Decision Support Techniques
2
2012
351
0.090
 Why?
Program Development
1
2012
346
0.090
 Why?
Lung Diseases
1
2017
703
0.090
 Why?
Ambulatory Care
2
2011
478
0.090
 Why?
Drug Resistance
1
2011
158
0.090
 Why?
Vitamin D Deficiency
1
2012
158
0.090
 Why?
Incidence
5
2020
2318
0.090
 Why?
Probability
1
2011
289
0.090
 Why?
Chi-Square Distribution
2
2017
498
0.090
 Why?
Bronchial Provocation Tests
2
2008
53
0.090
 Why?
Cross-Sectional Studies
6
2010
4411
0.090
 Why?
Algorithms
1
2017
1488
0.090
 Why?
Fluticasone
2
2008
87
0.090
 Why?
Vital Capacity
4
2017
257
0.090
 Why?
Immunoglobulin E
2
2008
323
0.080
 Why?
Surgical Wound Infection
1
2012
247
0.080
 Why?
Proportional Hazards Models
1
2012
1080
0.080
 Why?
Lectins, C-Type
1
2009
61
0.080
 Why?
Health Knowledge, Attitudes, Practice
2
2012
1184
0.080
 Why?
Receptors, Corticotropin-Releasing Hormone
1
2009
32
0.080
 Why?
Pandemics
3
2022
1321
0.080
 Why?
Smoking
3
2017
1392
0.080
 Why?
Health Services
2
2007
103
0.080
 Why?
Odds Ratio
4
2017
957
0.080
 Why?
Acute Disease
1
2011
915
0.080
 Why?
Kaplan-Meier Estimate
3
2016
814
0.080
 Why?
Medication Therapy Management
1
2010
67
0.080
 Why?
Vitamin K Epoxide Reductases
1
2008
11
0.080
 Why?
Cytochrome P-450 CYP2C9
1
2008
17
0.080
 Why?
Health Services Accessibility
2
2021
765
0.080
 Why?
Interviews as Topic
1
2011
584
0.080
 Why?
Eosinophil Cationic Protein
1
2008
9
0.080
 Why?
Genetic Predisposition to Disease
1
2016
2108
0.080
 Why?
Program Evaluation
1
2012
825
0.080
 Why?
Mixed Function Oxygenases
1
2008
36
0.080
 Why?
Aryl Hydrocarbon Hydroxylases
1
2008
41
0.080
 Why?
Genetic Techniques
1
2008
58
0.080
 Why?
Trastuzumab
1
2008
89
0.080
 Why?
Quality-Adjusted Life Years
2
2006
101
0.080
 Why?
Cost Sharing
1
2008
14
0.080
 Why?
Markov Chains
2
2006
114
0.080
 Why?
Exercise Tolerance
2
2022
213
0.080
 Why?
Insurance, Pharmaceutical Services
1
2008
23
0.080
 Why?
Smoking Cessation
1
2012
376
0.070
 Why?
Adrenergic beta-Agonists
1
2008
128
0.070
 Why?
Databases, Factual
1
2012
1132
0.070
 Why?
State Health Plans
1
2008
32
0.070
 Why?
Chronic Disease
3
2017
1591
0.070
 Why?
Reimbursement Mechanisms
1
2008
77
0.070
 Why?
Lung Diseases, Interstitial
1
2013
515
0.070
 Why?
Tomography, X-Ray Computed
1
2017
2341
0.070
 Why?
Antibodies, Anti-Idiotypic
1
2007
54
0.070
 Why?
Warfarin
1
2008
135
0.070
 Why?
Factor Analysis, Statistical
1
2008
257
0.070
 Why?
Omalizumab
1
2007
46
0.070
 Why?
Mycobacterium Infections, Nontuberculous
1
2012
336
0.070
 Why?
Health Surveys
2
2006
443
0.070
 Why?
Antiviral Agents
1
2012
647
0.070
 Why?
Influenza Vaccines
1
2012
496
0.070
 Why?
Animals, Domestic
1
2006
11
0.070
 Why?
Receptor, ErbB-2
1
2008
300
0.070
 Why?
Biomedical Research
1
2012
585
0.070
 Why?
Eosinophils
1
2008
281
0.070
 Why?
Infant
3
2008
7946
0.060
 Why?
Physicians, Family
2
2004
201
0.060
 Why?
Body Mass Index
3
2015
1967
0.060
 Why?
Models, Biological
1
2012
1636
0.060
 Why?
Health Benefit Plans, Employee
1
2005
20
0.060
 Why?
Clinical Competence
1
2012
899
0.060
 Why?
Health Policy
1
2008
333
0.060
 Why?
Database Management Systems
1
2005
48
0.060
 Why?
Mass Screening
1
2012
1012
0.060
 Why?
Hip Fractures
1
2006
75
0.060
 Why?
Patients
1
2006
162
0.060
 Why?
Prenatal Exposure Delayed Effects
1
2010
450
0.060
 Why?
Insurance Coverage
1
2006
201
0.060
 Why?
Patient Education as Topic
3
2005
682
0.060
 Why?
Gene Expression Profiling
1
2011
1523
0.060
 Why?
Utilization Review
1
2004
34
0.060
 Why?
Cost of Illness
2
2003
254
0.060
 Why?
Anticoagulants
1
2008
546
0.060
 Why?
Sex Factors
3
2016
1721
0.060
 Why?
Anti-Bacterial Agents
2
2004
1477
0.060
 Why?
Vaccination
1
2012
1205
0.060
 Why?
Medicaid
1
2008
409
0.060
 Why?
Circadian Rhythm
1
2006
354
0.050
 Why?
Parents
3
2006
1190
0.050
 Why?
Clinical Trials as Topic
2
2005
937
0.050
 Why?
Nitric Oxide
1
2008
827
0.050
 Why?
Attitude to Health
1
2006
405
0.050
 Why?
Case Management
1
2003
62
0.050
 Why?
Choice Behavior
1
2004
155
0.050
 Why?
Puerto Rico
1
2022
52
0.050
 Why?
Lung Neoplasms
1
2015
2201
0.050
 Why?
Symptom Flare Up
1
2022
38
0.050
 Why?
Sputum
1
2004
285
0.050
 Why?
Academies and Institutes
1
2022
44
0.050
 Why?
Minority Groups
1
2003
228
0.050
 Why?
Survival Rate
2
2016
1646
0.050
 Why?
Health Services Research
1
2004
371
0.050
 Why?
Clinical Trials, Phase II as Topic
1
2020
59
0.050
 Why?
Clinical Trials, Phase III as Topic
1
2020
82
0.040
 Why?
Electronics
1
2021
66
0.040
 Why?
Sample Size
1
2020
112
0.040
 Why?
Efficiency
1
2021
84
0.040
 Why?
Risk Assessment
3
2020
2976
0.040
 Why?
Language
1
2022
258
0.040
 Why?
Health Care Reform
1
2021
92
0.040
 Why?
Schools, Medical
1
2021
122
0.040
 Why?
Pragmatic Clinical Trials as Topic
1
2020
48
0.040
 Why?
Patient Selection
2
2020
646
0.040
 Why?
Stress, Psychological
1
2007
946
0.040
 Why?
Patient Compliance
2
2016
524
0.040
 Why?
Time
1
2019
71
0.040
 Why?
Health Education
1
2002
323
0.040
 Why?
Cluster Analysis
2
2014
458
0.040
 Why?
Quality of Health Care
1
2003
573
0.040
 Why?
Cooperative Behavior
1
2021
383
0.040
 Why?
Republic of Korea
1
2017
27
0.040
 Why?
Poland
1
2017
28
0.040
 Why?
Bronchitis, Chronic
1
2017
17
0.040
 Why?
Sensitivity and Specificity
3
2013
1715
0.040
 Why?
Patient-Centered Care
1
2003
474
0.040
 Why?
Nitrogen Dioxide
1
1997
20
0.040
 Why?
Antineoplastic Agents
1
2008
1879
0.040
 Why?
Long-Term Care
1
2018
76
0.040
 Why?
Pediatrics
1
2005
981
0.040
 Why?
Self Concept
1
2019
214
0.040
 Why?
Geography
1
2018
180
0.040
 Why?
Aftercare
1
2019
186
0.040
 Why?
Monitoring, Physiologic
2
2012
249
0.040
 Why?
Netherlands
1
2016
65
0.030
 Why?
Feasibility Studies
1
2020
746
0.030
 Why?
Tuberculosis, Pulmonary
1
2017
112
0.030
 Why?
Perception
1
2019
310
0.030
 Why?
Formoterol Fumarate
1
2015
7
0.030
 Why?
Forced Expiratory Flow Rates
1
2015
12
0.030
 Why?
Salmeterol Xinafoate
1
2015
41
0.030
 Why?
Ethanolamines
1
2015
19
0.030
 Why?
Receptors, Adrenergic, beta-2
1
2015
41
0.030
 Why?
Immunosuppressive Agents
2
2015
651
0.030
 Why?
Self Efficacy
1
2019
355
0.030
 Why?
Treatment Failure
1
2016
332
0.030
 Why?
Dose-Response Relationship, Drug
2
2011
1857
0.030
 Why?
Polymorphism, Single Nucleotide
2
2016
1901
0.030
 Why?
Postoperative Period
1
2016
292
0.030
 Why?
Age Factors
3
2008
2894
0.030
 Why?
Education
1
2015
95
0.030
 Why?
Pilot Projects
1
2020
1375
0.030
 Why?
Patient Acceptance of Health Care
1
2021
679
0.030
 Why?
Fatal Outcome
1
2015
285
0.030
 Why?
Biopsy
2
2013
1046
0.030
 Why?
Combined Modality Therapy
1
2017
1127
0.030
 Why?
Gene Expression
1
2018
1423
0.030
 Why?
Tissue Donors
1
2015
326
0.030
 Why?
Telephone
2
2005
152
0.030
 Why?
Extracorporeal Membrane Oxygenation
1
2015
240
0.030
 Why?
Lipopeptides
1
2012
14
0.030
 Why?
Echinocandins
1
2012
8
0.030
 Why?
Hypoxia
1
2019
958
0.030
 Why?
Intention to Treat Analysis
1
2012
68
0.030
 Why?
Amphotericin B
1
2012
30
0.030
 Why?
Aspergillosis
1
2012
23
0.030
 Why?
Candidiasis
1
2012
52
0.030
 Why?
Transplantation, Homologous
1
2013
390
0.020
 Why?
Age Distribution
2
2003
340
0.020
 Why?
Mycobacterium avium Complex
1
2012
92
0.020
 Why?
Triazoles
1
2012
130
0.020
 Why?
Cromolyn Sodium
2
2001
13
0.020
 Why?
Colorado
1
2021
4089
0.020
 Why?
Self Care
2
2005
351
0.020
 Why?
Leukotriene Antagonists
1
2011
41
0.020
 Why?
Reference Values
1
2012
748
0.020
 Why?
Functional Residual Capacity
1
2010
7
0.020
 Why?
Costa Rica
1
2010
16
0.020
 Why?
Genome-Wide Association Study
1
2016
1203
0.020
 Why?
Principal Component Analysis
1
2011
176
0.020
 Why?
Health
1
2010
74
0.020
 Why?
Nontuberculous Mycobacteria
1
2012
206
0.020
 Why?
Inhalation
1
2010
26
0.020
 Why?
Prospective Studies
2
2012
6232
0.020
 Why?
Environment
1
2011
335
0.020
 Why?
Observation
1
2008
49
0.020
 Why?
Sex Ratio
1
2008
14
0.020
 Why?
Least-Squares Analysis
1
2008
73
0.020
 Why?
Models, Econometric
1
2008
34
0.020
 Why?
Health Services Administration
1
2007
7
0.020
 Why?
Social Isolation
1
2007
52
0.020
 Why?
Treatment Refusal
1
2008
85
0.020
 Why?
Puberty
1
2008
137
0.020
 Why?
Intelligence
1
2007
132
0.020
 Why?
Body Weight
1
2011
873
0.020
 Why?
Exercise
1
2016
1644
0.020
 Why?
Child Behavior Disorders
1
2007
131
0.020
 Why?
Animals
1
2006
31867
0.020
 Why?
Insurance, Health
1
2007
244
0.020
 Why?
CD4-Positive T-Lymphocytes
1
2011
965
0.020
 Why?
Genotype
1
2009
1780
0.010
 Why?
Bronchoconstrictor Agents
1
2003
14
0.010
 Why?
Case-Control Studies
1
2010
3015
0.010
 Why?
Health Status Indicators
1
2004
154
0.010
 Why?
Organizational Innovation
1
2004
133
0.010
 Why?
Systems Integration
1
2003
38
0.010
 Why?
Computer Systems
1
2003
46
0.010
 Why?
Motor Activity
1
2007
642
0.010
 Why?
Child Welfare
1
2004
192
0.010
 Why?
Self Disclosure
1
2002
59
0.010
 Why?
Histamine H1 Antagonists
1
2002
33
0.010
 Why?
Drug Administration Schedule
1
2004
719
0.010
 Why?
Administration, Intranasal
1
2002
75
0.010
 Why?
Nurse's Role
1
2003
105
0.010
 Why?
Point-of-Care Systems
1
2003
139
0.010
 Why?
Confidence Intervals
1
2002
306
0.010
 Why?
Regression Analysis
1
2003
948
0.010
 Why?
Caregivers
1
2007
712
0.010
 Why?
Health Care Surveys
1
2002
538
0.010
 Why?
Sex Distribution
1
2001
335
0.010
 Why?
Decision Support Systems, Clinical
1
2003
177
0.010
 Why?
Patient Satisfaction
1
2004
580
0.010
 Why?
Disease Management
1
2003
563
0.010
 Why?
Linear Models
1
2002
776
0.010
 Why?
Pregnancy
1
2010
5521
0.010
 Why?
Internet
1
2003
600
0.010
 Why?
Bronchoscopy
1
2000
244
0.010
 Why?
Survival Analysis
1
2000
1211
0.010
 Why?
Infant, Newborn
1
2004
5041
0.010
 Why?
Fuhlbrigge's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (426) concept(s)
_
Co-Authors Expand Description
See all (17) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)